FWD-K01

FWD-K01 is a potent and selective small molecule covalent inhibitor of the KRAS G12C mutant protein, currently under development by Shenzhen Forward Pharmaceuticals. KRAS is a small GTPase that cycles between active GTP-bound and inactive GDP-bound states; the G12C mutation (glycine-to-cysteine at codon 12) impairs the intrinsic GTPase activity, favoring the active state and promoting oncogenic signaling through the MAPK and PI3K pathways. FWD-K01 specifically targets the cysteine residue of the G12C mutant, locking the protein in its inactive GDP-bound conformation. This mechanism effectively shuts down downstream signaling, leading to the inhibition of tumor growth in KRAS G12C-mutated cancers, such as non-small cell lung cancer (NSCLC) and colorectal cancer. It is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors.